The hallmarks of successful anticancer immunotherapy

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · see citing works

Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018.

Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680 · see citing works

Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · see citing works

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · see citing works

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · see citing works

The Immune Landscape of Cancer

Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870 · see citing works

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735 · see citing works

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671 · see citing works

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400 · see citing works

Elements of cancer immunity and the cancer–immune set point

Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · see citing works

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients

Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · see citing works

Neoantigens in cancer immunotherapy

Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783 · see citing works

The biology and function of fibroblasts in cancer

Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366 · see citing works

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · see citing works

Commensal <i>Bifidobacterium</i> promotes antitumor immunity and facilitates anti–PD-L1 efficacy

Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · see citing works

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669 · see citing works

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A. S., Scott, E. C., Gutierrez, M. E., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,564 · see citing works

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · see citing works

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression

Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331 · see citing works

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · see citing works

Car t cell immunotherapy for human cancer

June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207 · see citing works

Immunogenic cell death in cancer and infectious disease

Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119 · see citing works

Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden

Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063 · see citing works

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839 · see citing works

Type I interferons in infectious disease

McNab, F., Mayer-Barber, K., Sher, A., Wack, A., & O'Garra, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3787 · Cited by 2,780 · see citing works

Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival

Özdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C.-C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.005 · Cited by 2,681 · see citing works

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

Riaz, N., Havel, J. J., Makarov, V., Desrichard, A., Urba, W. J., Sims, J. S., Hodi, F. S., Martín-Algarra, S., Mandal, R., Sharfman, W. H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.028 · Cited by 2,401 · see citing works

Tracking the Evolution of Non–Small-Cell Lung Cancer

Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B. K., Veeriah, S., Shafi, S., Johnson, D. H., Mitter, R., Rosenthal, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616288 · Cited by 2,349 · see citing works

Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential

Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345 · see citing works

The immune contexture in cancer prognosis and treatment

Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263 · see citing works

Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment

Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., Molina, D. A., Salcedo, R., Back, T., Cramer, S., et al. (2013) · Science · doi:10.1126/science.1240527 · Cited by 2,251 · see citing works

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32455-2 · Cited by 2,199 · see citing works

The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide

Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050 · see citing works

LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells

Brand, A., Singer, K., Koehl, G. E., Kolitzus, M., Schoenhammer, G., Thiel, A., Matos, C., Bruss, C., Klobuch, S., Peter, K., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.011 · Cited by 2,039 · see citing works

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974 · see citing works

Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry

Giesen, C., Wang, H. A. O., Schapiro, D., Zivanovic, N., Jacobs, A., Hattendorf, B., Schüffler, P. J., Grolimund, D., Buhmann, J. M., Brandt, S., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2869 · Cited by 1,951 · see citing works

Regulation and Functions of the IL-10 Family of Cytokines in Inflammation and Disease

Ouyang, W., Rutz, S., Crellin, N. K., Valdez, P. A., & Hymowitz, S. G. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101312 · Cited by 1,932 · see citing works

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

Abbosh, C., Birkbak, N. J., Wilson, G. A., Jamal‐Hanjani, M., Constantin, T. P., Salari, R., Quesne, J. P. C. L., Moore, D. A., Veeriah, S., Rosenthal, R., et al. (2017) · Nature · doi:10.1038/nature22364 · Cited by 1,880 · see citing works

NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control

Böttcher, J. P., Bonavita, E., Chakravarty, P., Blees, H., Cabeza-Cabrerizo, M., Sammicheli, S., Rogers, N. C., Sahai, E., Zelenay, S., & Reis e Sousa, C. (2018) · Cell · doi:10.1016/j.cell.2018.01.004 · Cited by 1,857 · see citing works

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851 · see citing works

DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity

Vanpouille-Box, C., Alard, A., Aryankalayil, M. J., Sarfraz, Y., Diamond, J. M., Schneider, R. J., Inghirami, G., Coleman, C. N., Formenti, S. C., & Demaria, S. (2017) · Nature Communications · doi:10.1038/ncomms15618 · Cited by 1,834 · see citing works

Myeloid-derived suppressor cells coming of age

Veglia, F., Perego, M., & Gabrilovich, D. I. (2018) · Nature Immunology · doi:10.1038/s41590-017-0022-x · Cited by 1,774 · see citing works

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

Huang, A. C., Postow, M. A., Orlowski, R. J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J. R., Wenz, B., et al. (2017) · Nature · doi:10.1038/nature22079 · Cited by 1,664 · see citing works

Universal Patterns of Selection in Cancer and Somatic Tissues

Martincorena, I., Raine, K. M., Gerstung, M., Dawson, K. J., Haase, K., Van Loo, P., Davies, H., Stratton, M. R., & Campbell, P. J. (2017) · Cell · doi:10.1016/j.cell.2017.09.042 · Cited by 1,523 · see citing works

Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses

Ho, P.-C., Bihuniak, J. D., Macintyre, A. N., Staron, M., Liu, X., Amezquita, R., Tsui, Y.-C., Cui, G., Micevic, G., Perales, J. C., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.012 · Cited by 1,462 · see citing works

Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy

Spranger, S., Dai, D., Horton, B., & Gajewski, T. F. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.003 · Cited by 1,441 · see citing works

The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression

Pushalkar, S., Hundeyin, M., Daley, D., Zambirinis, C. P., Kurz, E., Mishra, A., Mohan, N., Aykut, B., Usyk, M., Torres, L. E., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1134 · Cited by 1,400 · see citing works

Primary Resistance to PD-1 Blockade Mediated by <i>JAK1/2</i> Mutations

Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337 · see citing works

Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy

Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300 · see citing works

Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution

McGranahan, N., Rosenthal, R., Hiley, C. T., Rowan, A. J., Watkins, T. B. K., Wilson, G. A., Birkbak, N. J., Veeriah, S., Van Loo, P., Herrero, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.001 · Cited by 1,298 · see citing works

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

Miao, D., Margolis, C. A., Gao, W., Voss, M. H., Li, W., Martini, D. J., Norton, C., Bossé, D., Wankowicz, S. M., Cullen, D., et al. (2018) · Science · doi:10.1126/science.aan5951 · Cited by 1,249 · see citing works

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade

Benci, J. L., Xu, B., Qiu, Y., Wu, T. J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D. S. M., Pauken, K. E., Huang, A. C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.022 · Cited by 1,216 · see citing works

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer

Initiative, A. P. C. G., Balachandran, V. P., Łuksza, M., Zhao, J. N., Makarov, V., Moral, J. A., Remark, R., Herbst, B., Askan, G., Bhanot, U., et al. (2017) · Nature · doi:10.1038/nature24462 · Cited by 1,191 · see citing works

Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition

Salmon, H., Idoyaga, J., Rahman, A. H., Leboeuf, M., Remark, R., Jordan, S., Casanova-Acebes, M., Khudoynazarova, M. N., Agudo, J., Tung, N., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.03.012 · Cited by 1,187 · see citing works

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142 · see citing works

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

Boutros, C., Tarhini, A. A., Routier, É., Lambotte, O., Ladurie, F. L. R., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,090 · see citing works

Variation in the Human Immune System Is Largely Driven by Non-Heritable Influences

Brodin, P., Jojic, V., Gao, T., Bhattacharya, S., Angel, C. J. L., Furman, D., Shen-Orr, S., Dekker, C. L., Swan, G. E., Butte, A. J., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.020 · Cited by 1,065 · see citing works

Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy

Jiang, H., Hegde, S., Knolhoff, B. L., Zhu, Y., Herndon, J. M., Meyer, M. A., Nywening, T. M., Hawkins, W. G., Shapiro, I. M., Weaver, D. T., et al. (2016) · Nature Medicine · doi:10.1038/nm.4123 · Cited by 1,060 · see citing works

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042 · see citing works

Monitoring immune-checkpoint blockade: response evaluation and biomarker development

Nishino, M., Ramaiya, N. H., Hatabu, H., & Hodi, F. S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.88 · Cited by 1,023 · see citing works

Resistance to checkpoint blockade therapy through inactivation of antigen presentation

Sade-Feldman, M., Jiao, Y. J., Chen, J. H., Rooney, M. S., Barzily-Rokni, M., Eliane, J.-P., Bjorgaard, S. L., Hammond, M. R., Vitzthum, H., Blackmon, S. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01062-w · Cited by 1,005 · see citing works

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis

Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms10391 · Cited by 987 · see citing works

Tumor Endothelium FasL Establishes a Selective Immune Barrier Promoting Tolerance in Tumors

Motz, G. T., Santoro, S. P., Wang, L.-P., Garrabrant, T., Lastra, R., Hagemann, I., Lal, P., Feldman, M., Benencia, F., & Coukos, G. (2014) · Nature Medicine · doi:10.1038/nm.3541 · Cited by 980 · see citing works

The ectonucleotidases <scp>CD</scp> 39 and <scp>CD</scp> 73: Novel checkpoint inhibitor targets

Allard, B., Longhi, M. S., Robson, S. C., & Stagg, J. (2017) · Immunological Reviews · doi:10.1111/imr.12528 · Cited by 927 · see citing works

Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects

Daillère, R., Vétizou, M., Waldschmitt, N., Yamazaki, T., Isnard, C., Poirier-Colame, V., Duong, C. P. M., Flament, C., Lepage, P., Roberti, M. P., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.09.009 · Cited by 897 · see citing works

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

Hellmann, M. D., Callahan, M. K., Awad, M. M., Calvo, E., Ascierto, P. A., Atmaca, A., Rizvi, N. A., Hirsch, F. R., Selvaggi, G., Szustakowski, J. D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.001 · Cited by 892 · see citing works

Identification of essential genes for cancer immunotherapy

Patel, S. J., Sanjana, N. E., Kishton, R. J., Eidizadeh, A., Vodnala, S. K., Cam, M., Gartner, J. J., Jia, L., Steinberg, S. M., Yamamoto, T. N., et al. (2017) · Nature · doi:10.1038/nature23477 · Cited by 870 · see citing works

Wild Mouse Gut Microbiota Promotes Host Fitness and Improves Disease Resistance

Rosshart, S. P., Vassallo, B. G., Angeletti, D., Hutchinson, D. S., Morgan, A. P., Takeda, K., Hickman, H. D., McCulloch, J. A., Badger, J. H., Ajami, N. J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.016 · Cited by 862 · see citing works

TGF-β Activation and Function in Immunity

Travis, M. A., & Sheppard, D. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120257 · Cited by 856 · see citing works

Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming

Tian, L., Goldstein, A., Wang, H., Ching Lo, H., Sun Kim, I., Welte, T., Sheng, K., Dobrolecki, L. E., Zhang, X., Putluri, N., et al. (2017) · Nature · doi:10.1038/nature21724 · Cited by 841 · see citing works

Cancer classification using the Immunoscore: a worldwide task force

Galon, J., Pagès, F., Marincola, F. M., Angell, H. K., Thurin, M., Lugli, A., Zlobec, I., Berger, A., Bifulco, C. B., Botti, G., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-205 · Cited by 790 · see citing works

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

Gettinger, S., Choi, J., Hastings, K., Truini, A., Datar, I., Sowell, R., Wurtz, A., Dong, W., Cai, G., Melnick, M. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0593 · Cited by 787 · see citing works

The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies

Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aar6918 · Cited by 777 · see citing works

Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor

Maj, T., Wang, W., Crespo, J., Zhang, H., Wang, W., Wei, S., Zhao, L., Vatan, L., Shao, I., Szeliga, W., et al. (2017) · Nature Immunology · doi:10.1038/ni.3868 · Cited by 733 · see citing works

Control of Metastasis by NK Cells

López‐Soto, A., Gonzalez, S. R., Smyth, M. J., & Galluzzi, L. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.009 · Cited by 730 · see citing works

Metabolic targets for cancer therapy

Galluzzi, L., Kepp, O., Heiden, M. G. V., & Kroemer, G. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4145 · Cited by 705 · see citing works

Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells

Ma, Y., Adjemian, S., Mattarollo, S. R., Yamazaki, T., Aymeric, L., Yang, H., Catani, J. P. P., Hannani, D., Duret, H., Steegh, K., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.03.003 · Cited by 698 · see citing works

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators

Mezzadra, R., Sun, C., Jae, L. T., Gomez-Eerland, R., de Vries, E., Wu, W., Logtenberg, M. E. W., Slagter, M., Rozeman, E. A., Hofland, I., et al. (2017) · Nature · doi:10.1038/nature23669 · Cited by 697 · see citing works

VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer

Terme, M., Pernot, S., Marcheteau, E., Sandoval, F., Benhamouda, N., Colussi, O., Dubreuil, O., Carpentier, A. F., Tartour, E., & Taieb, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2325 · Cited by 684 · see citing works

First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication

Lemery, S. J., Keegan, P., & Pazdur, R. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmp1709968 · Cited by 664 · see citing works

Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells

Gao, Y., Souza-Fonseca-Guimarães, F., Bald, T., Ng, S. S., Young, A., Ngiow, S. F., Rautela, J., Straube, J., Waddell, N., Blake, S. J., et al. (2017) · Nature Immunology · doi:10.1038/ni.3800 · Cited by 654 · see citing works

Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors

Kumar, V., Donthireddy, L., Marvel, D., Condamine, T., Wang, F., Lavilla-Alonso, S., Hashimoto, A., Vonteddu, P., Behera, R., Goins, M. A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.005 · Cited by 653 · see citing works

Defining the role of the tumor vasculature in antitumor immunity and immunotherapy

Schaaf, M. B., Garg, A. D., & Agostinis, P. (2018) · Cell Death &amp; Disease · doi:10.1038/s41419-017-0061-0 · Cited by 629 · see citing works

A neoantigen fitness model predicts tumor response to checkpoint blockade immunotherapy

Łuksza, M., Riaz, N., Makarov, V., Balachandran, V., Hellmann, M., Solovyov, A., Rizvi, N., Merghoub, T., Levine, A., Chan, T., et al. (2017) · Nature · doi:10.1038/nature24473 · Cited by 624 · see citing works

Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy

Shalapour, S., Font-Burgada, J., Di Caro, G., Zhong, Z., Sanchez-Lopez, E., Dhar, D., Willimsky, G., Ammirante, M., Strasner, A., Hansel, D. E., et al. (2015) · Nature · doi:10.1038/nature14395 · Cited by 611 · see citing works

Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations

Hoos, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.35 · Cited by 601 · see citing works

Inflammasomes in carcinogenesis and anticancer immune responses

Zitvogel, L., Kepp, O., Galluzzi, L., & Kroemer, G. (2012) · Nature Immunology · doi:10.1038/ni.2224 · Cited by 593 · see citing works

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.010 · Cited by 592 · see citing works

Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway

Liu, J., Hamrouni, A., Wołowiec, D., Coiteux, V., Kuliczkowski, K., Hétuin, D., Saudemont, A., & Quesnel, B. (2007) · Blood · doi:10.1182/blood-2006-10-051482 · Cited by 580 · see citing works

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma

Rodig, S. J., Gusenleitner, D., Jackson, D. G., Gjini, E., Giobbie-Hurder, A., Jin, C., Chang, H., Lovitch, S. B., Horak, C., Weber, J. S., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar3342 · Cited by 579 · see citing works

Cancer-associated fibroblasts induce antigen-specific deletion of CD8 + T Cells to protect tumour cells

Lakins, M. A., Ghorani, E., Munir, H., Martins, C. P., & Shields, J. D. (2018) · Nature Communications · doi:10.1038/s41467-018-03347-0 · Cited by 578 · see citing works

Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer

Le, D. T., Lutz, E. R., Uram, J. N., Sugar, E. A., Onners, B., Solt, S., Zheng, L., Diaz, L. A., Donehower, R. C., Jaffee, E. M., et al. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31829fb7a2 · Cited by 566 · see citing works

Fundamental limits of spatial resolution in PET

Moses, W. W. (2010) · Nuclear Instruments and Methods in Physics Research Section A Accelerators Spectrometers Detectors and Associated Equipment · doi:10.1016/j.nima.2010.11.092 · Cited by 565 · see citing works

An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression

Palazon, A., Tyrakis, P. A., Macias, D., Veliça, P., Rundqvist, H., Fitzpatrick, S., Vojnovic, N., Phan, A. T., Loman, N., Hedenfalk, I., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.003 · Cited by 521 · see citing works

Classification of current anticancer immunotherapies

Galluzzi, L., Vacchelli, E., Pedro, J. M. B., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 471 · see citing works

Cancer and the gut microbiota: An unexpected link

Zitvogel, L., Galluzzi, L., Viaud, S., Vétizou, M., Daillère, R., Merad, M., & Kroemer, G. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010473 · Cited by 465 · see citing works

Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity

de Andrade, L. F., Tay, R. E., Pan, D., Luoma, A., Ito, Y., Badrinath, S., Tsoucas, D. M., Franz, B., May, K. F., Harvey, C. J., et al. (2018) · Science · doi:10.1126/science.aao0505 · Cited by 464 · see citing works

A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Beatty, G. L., Torigian, D. A., Chiorean, E. G., Saboury, B., Brothers, A., Alavi, A. A., Troxel, A. B., Sun, W., Teitelbaum, U. R., Vonderheide, R. H., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1320 · Cited by 458 · see citing works

The spectrum of T cell metabolism in health and disease

Bantug, G. R., Galluzzi, L., Kroemer, G., & Hess, C. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.99 · Cited by 421 · see citing works

Association ofFusobacteriumspecies in pancreatic cancer tissues with molecular features and prognosis

Mitsuhashi, K., Nosho, K., Sukawa, Y., Matsunaga, Y., Ito, M., Kurihara, H., Kanno, S., Igarashi, H., Naito, T., Adachi, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3109 · Cited by 404 · see citing works

Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses

Young, A., Ngiow, S. F., Barkauskas, D. S., Sult, E., Hay, C. M., Blake, S. J., Huang, Q., Liu, J., Takeda, K., Teng, M. W. L., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.025 · Cited by 389 · see citing works

Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade

Zhou, J. M., Mahoney, K. M., Giobbie‐Hurder, A., Zhao, F., Lee, S., Liao, X., Rodig, S. J., Li, J., Wu, X., Butterfield, L. H., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0329 · Cited by 353 · see citing works

Immunoregulation by members of the TGFβ superfamily

Chen, W., & ten Dijke, P. (2016) · Nature reviews. Immunology · doi:10.1038/nri.2016.112 · Cited by 347 · see citing works

Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia

Baginska, J., Viry, E., Berchem, G., Poli, A., Noman, M. Z., van Moer, K., Medves, S., Zimmer, J., Oudin, A., Niclou, S. P., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304790110 · Cited by 344 · see citing works

Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors

Delahaye, N. F., Rusakiewicz, S., Martins, I., Menard, C., Roux, S., Lyonnet, L., Paul, P., Sarabi, M., Chaput, N., Semeraro, M., et al. (2011) · Nature Medicine · doi:10.1038/nm.2366 · Cited by 338 · see citing works

High response rate to PD-1 blockade in desmoplastic melanomas

Eroglu, Z., Zaretsky, J. M., Hu-Lieskovan, S., Kim, D. W., Algazi, A., Johnson, D. B., Liniker, E., Kong, B., Munhoz, R., Rapisuwon, S., et al. (2018) · Nature · doi:10.1038/nature25187 · Cited by 338 · see citing works

Emerging concepts of T cell metabolism as a target of immunotherapy

Chang, C., & Pearce, E. L. (2016) · Nature Immunology · doi:10.1038/ni.3415 · Cited by 337 · see citing works

A Relay Pathway between Arginine and Tryptophan Metabolism Confers Immunosuppressive Properties on Dendritic Cells

Mondanelli, G., Bianchi, R., Pallotta, M. T., Orabona, C., Albini, E., Iacono, A., Belladonna, M. L., Vacca, C., Fallarino, F., Macchiarulo, A., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.01.005 · Cited by 335 · see citing works

Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy

Ravi, R., Noonan, K. A., Pham, V., Bedi, R., Zhavoronkov, A., Ozerov, I. V., Makarev, E., V. Artemov, A., Wysocki, P. T., Mehra, R., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02696-6 · Cited by 325 · see citing works

Anti–PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM

Mathios, D., Kim, J. E., Mangraviti, A., Phallen, J. A., Park, C., Jackson, C. M., Garzón-Muvdi, T., Kim, E. S., Theodros, D., Polanczyk, M. J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag2942 · Cited by 301 · see citing works

High-Dimensional Phenotypic Mapping of Human Dendritic Cells Reveals Interindividual Variation and Tissue Specialization

Alcántara‐Hernández, M., Leylek, R. A., Wagar, L. E., Engleman, E. G., Keler, T., Marinkovich, M. P., Davis, M. M., Nolan, G. P., & Idoyaga, J. (2017) · Immunity · doi:10.1016/j.immuni.2017.11.001 · Cited by 299 · see citing works

The Mechanisms of T Cell Selection in the Thymus

Takaba, H., & Takayanagi, H. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.07.010 · Cited by 292 · see citing works

Targeting CD73 in the tumor microenvironment with MEDI9447

Hay, C. M., Sult, E., Huang, Q., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1208875 · Cited by 290 · see citing works

The autophagic network and cancer

Rybstein, M. D., Pedro, J. M. B., Kroemer, G., & Galluzzi, L. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0042-2 · Cited by 287 · see citing works

Increased vessel perfusion predicts the efficacy of immune checkpoint blockade

Zheng, X., Fang, Z., Liu, X., Deng, S., Zhou, P., Wang, X., Zhang, C., Yin, R., Hu, H., Chen, X., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96582 · Cited by 239 · see citing works

Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial

Buisseret, L., Pommey, S., Allard, B., Garaud, S., Bergeron, M., Cousineau, I., Ameye, L., Barèche, Y., Paesmans, M., Crown, J. P., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx730 · Cited by 233 · see citing works

IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity

Molgora, M., Bonavita, E., Ponzetta, A., Riva, F., Barbagallo, M., Jaillon, S., Popović, B., Bernardini, G., Magrini, E. I., Gianni, F., et al. (2017) · Nature · doi:10.1038/nature24293 · Cited by 228 · see citing works

NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis

Glasner, A., Levi, A., Enk, J., Isaacson, B., Viukov, S. V., Orlanski, S., Scope, A., Neuman, T., Enk, C. D., Hanna, J. H., et al. (2018) · Immunity · doi:10.1016/j.immuni.2017.12.007 · Cited by 223 · see citing works

Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity

Hoves, S., Ooi, C.-H., Wolter, C., Sade, H., Bissinger, S., Schmittnaegel, M., Ast, O., Giusti, A. M., Wartha, K., Runza, V., et al. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20171440 · Cited by 219 · see citing works

Lymphatic vessels regulate immune microenvironments in human and murine melanoma

Lund, A. W., Wagner, M., Fankhauser, M., Steinskog, E. S. S., Broggi, M. A. S., Spranger, S., Gajewski, T. F., Alitalo, K. K., Eikesdal, H. P., Wiig, H., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci79434 · Cited by 212 · see citing works

Natural Killer Cell IFN-γ Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor–Bearing Patients

Ménard, C., Blay, J.-Y., Borg, C., Michiels, S., Ghiringhelli, F., Robert, C., Nonn, C., Chaput, N., Taïeb, J., Delahaye, N. F., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3807 · Cited by 202 · see citing works

Predictors of responses to immune checkpoint blockade in advanced melanoma

Jacquelot, N., Roberti, M. P., Enot, D. P., Rusakiewicz, S., Ternès, N., Jegou, S., Woods, D. M., Sodré, A. L., Hansen, M., Meirow, Y., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00608-2 · Cited by 196 · see citing works

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients

Subrahmanyam, P. B., Dong, Z., Gusenleitner, D., Giobbie-Hurder, A., Severgnini, M., Zhou, J., Manos, M., Eastman, L. M., Maecker, H. T., & Hodi, F. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0328-8 · Cited by 190 · see citing works

Redirecting T cells to hematological malignancies with bispecific antibodies

Velasquez, M. P., Bonifant, C. L., & Gottschalk, S. M. (2017) · Blood · doi:10.1182/blood-2017-06-741058 · Cited by 174 · see citing works

Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade

Shukla, S. A., Bachireddy, P., Schilling, B., Galonska, C., Zhan, Q., Bango, C., Langer, R., Lee, P. C., Gusenleitner, D., Keskin, D. B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.026 · Cited by 174 · see citing works

PD-L1 Testing in Cancer

Hansen, A. R., & Siu, L. L. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4685 · Cited by 157 · see citing works

Tumor-Associated Lymphatic Vessels Upregulate PDL1 to Inhibit T-Cell Activation

Dieterich, L. C., Ikenberg, K., Cetintas, T., Kapaklikaya, K., Hutmacher, C., & Detmar, M. J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00066 · Cited by 144 · see citing works

miR-25/93 mediates hypoxia-induced immunosuppression by repressing cGAS

Wu, M.-Z., Cheng, W., Chen, S.-F., Nieh, S., O’Connor, C., Liu, C., Tsai, W., Wu, C.-J., Martin, L., Lin, Y., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3615 · Cited by 139 · see citing works

Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers

Ock, C.-Y., Hwang, J., Keam, B., Kim, S.-B., Shim, J., Jang, H.-J., Park, S., Sohn, B. H., Cha, M., Ajani, J. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01018-0 · Cited by 135 · see citing works

Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes

Kitano, S., Postow, M. A., Ziegler, C. G. K., Kuk, D., Panageas, K. S., Cortez, C. A., Rasalan, T. S., Adamow, M. J., Yuan, J. D., Wong, P., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0013 · Cited by 130 · see citing works

DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune cell activation

Xiao, Q., Wu, J., Wang, W.-J., Chen, S., Zheng, Y., Yu, X., Meeth, K., Sahraei, M., Bothwell, A. L. M., Chen, L., et al. (2018) · Nature Medicine · doi:10.1038/nm.4496 · Cited by 130 · see citing works

Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy.

(2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2165 · Cited by 127 · see citing works

Treating with Checkpoint Inhibitors-Figure $1 Million per Patient.

Andrews, A. (2015) · PubMed · Cited by 126 · see citing works

Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells

Dai, P., Wang, W., Yang, N., Serna‐Tamayo, C., Ricca, J. M., Zamarin, D., Shuman, S., Merghoub, T., Wolchok, J. D., & Deng, L. (2017) · Science Immunology · doi:10.1126/sciimmunol.aal1713 · Cited by 123 · see citing works

Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity

Perry, C. J., Muñoz-Rojas, A., Meeth, K., Kellman, L. N., Amezquita, R., Thakral, D., Du, V. Y., Wang, J. X., Damsky, W., Kuhlmann, A., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171435 · Cited by 121 · see citing works

CD19 CAR T Cells

Sadelain, M. (2017) · Cell · doi:10.1016/j.cell.2017.12.002 · Cited by 120 · see citing works

ITPR1 Protects Renal Cancer Cells against Natural Killer Cells by Inducing Autophagy

Messai, Y., Noman, M. Z., Hasmim, M., Janji, B., Tittarelli, A., Boutet, M., Baud, V., Viry, E., Billot, K., Nanbakhsh, A., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0303 · Cited by 119 · see citing works

Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells

Maurer, S., Kropp, K. N., Klein, G., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1364827 · Cited by 115 · see citing works

Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer

Gavin, P. G., Song, N., Kim, S. R., Lipchik, C., Johnson, N. L., Bandos, H., Finnigan, M., Rastogi, P., Fehrenbacher, L., Mamounas, E. P., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4884 · Cited by 113 · see citing works

Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma

Kikuchi, M., Clump, D. A., Srivastava, R. M., Sun, L., Zeng, D., Díaz-Pérez, J. A., Anderson, C. J., Edwards, W. B., & Ferris, R. L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1329071 · Cited by 111 · see citing works

Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab

Morello, S., Capone, M., Sorrentino, C., Giannarelli, D., Madonna, G., Mallardo, D., Grimaldi, A. M., Pinto, A., & Ascierto, P. A. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1348-8 · Cited by 101 · see citing works

ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells

Lecciso, M., Očadlíková, D., Sangaletti, S., Trabanelli, S., Marchi, E. D., Orioli, E., Pegoraro, A., Portararo, P., Jandus, C., Bontadini, A., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01918 · Cited by 96 · see citing works

Regulatory T cells with multiple suppressive and potentially pro-tumor activities accumulate in human colorectal cancer

Timperi, E., Pacella, I., Schinzari, V., Focaccetti, C., Sacco, L., Farelli, F., Caronna, R., Bene, G. D., Longo, F., Ciardi, A., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1175800 · Cited by 81 · see citing works

Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors

Conroy, J. M., Pabla, S., Glenn, S. T., Burgher, B., Nesline, M., Papanicolau‐Sengos, A., Andreas, J., Giamo, V., Lenzo, F. L., Hyland, F. C. L., et al. (2017) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2017.10.001 · Cited by 80 · see citing works

Autocrine Adenosine Regulates Tumor Polyfunctional CD73+CD4+ Effector T Cells Devoid of Immune Checkpoints

Gourdin, N., Bossennec, M., Rodriguez, C., Viganó, S., Machon, C., Jandus, C., Bauché, D., Faget, J., Durand, I., Chopin, N., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2405 · Cited by 72 · see citing works

Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy

Facciabene, A., Sanctis, F. D., Pierini, S., Reis, E. S., Balint, K., Facciponte, J. G., Rueter, J., Kagabu, M., Magotti, P., Lanitis, E., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1326442 · Cited by 69 · see citing works

IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients

Tallerico, R., Cristiani, C. M., Staaf, E., Garofalo, C., Sottile, R., Capone, M., de Coaña, Y. P., Madonna, G., Palella, E., Wolodarski, M., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1261242 · Cited by 68 · see citing works

Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells

Audenaerde, J. R. M. V., Waele, J. D., Marcq, E., Loenhout, J. V., Lion, E., den Bergh, J. M. J. V., Jesenofsky, R., Masamune, A., Roeyen, G., Pauwels, P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18185 · Cited by 68 · see citing works

Targeting Vascular Endothelial-Cadherin in Tumor-Associated Blood Vessels Promotes T-cell–Mediated Immunotherapy

Zhao, Y., Ting, K. K., Li, J., Cogger, V. C., Chen, J., Johansson, A., Ngiow, S. F., Holst, J., Grau, G. E., Goel, S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3129 · Cited by 61 · see citing works

Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients

Marcq, E., Waele, J. D., Audenaerde, J. R. M. V., Lion, E., Santermans, E., Hens, N., Pauwels, P., van Meerbeeck, J. P., & Smits, E. (2017) · Oncotarget · doi:10.18632/oncotarget.21113 · Cited by 58 · see citing works

Targeting stroma in pancreatic cancer: Promises and failures of targeted therapies

Bahrami, A., Khazaei, M., Bagherieh, F., Ghayour‐Mobarhan, M., Maftouh, M., Hassanian, S. M., & Avan, A. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25798 · Cited by 46 · see citing works

Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors

Lu, S., Zhang, J., Liu, D., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0845 · Cited by 44 · see citing works

Soluble NKG2D ligands in the ovarian cancer microenvironment are associated with an adverse clinical outcome and decreased memory effector T cells independent of NKG2D downregulation

Vyas, M., Reinartz, S., Hoffmann, N., Reiners, K. S., Lieber, S., Jansen, J. M., Wagner, U. A. G., Müller, R., & von Strandmann, E. P. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1339854 · Cited by 44 · see citing works

Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study

Maccalli, C., Giannarelli, D., Capocefalo, F., Pilla, L., Fonsatti, E., Giacomo, A. M. D., Parmiani, G., & Maio, M. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1071007 · Cited by 32 · see citing works

Multiplexed PET Probes for Imaging Breast Cancer Early Response to VEGF121/rGel Treatment

Yang, M., Gao, H., Sun, X., et al. (2011) · Molecular Pharmaceutics · doi:10.1021/mp100446t · Cited by 27 · see citing works

PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab

George, S., Papanicolau‐Sengos, A., Lenzo, F. L., Conroy, J. M., Nesline, M., Pabla, S., Glenn, S. T., Burgher, B., Andreas, J., Giamo, V., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1460298 · Cited by 20 · see citing works

Macrophages and metabolism in the tumor microenvironment

Vitale, I., Manic, G., Coussens, L. M., Kroemer, G., & Galluzzi, L. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.001 · Cited by 1,837 · see citing works

Autophagy in major human diseases

Klionsky, D. J., Petroni, G., Amaravadi, R. K., Baehrecke, E. H., Ballabio, A., Boya, P., Bravo‐San Pedro, J. M., Cadwell, K., Cecconi, F., Choi, A. M. K., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021108863 · Cited by 1,585 · see citing works

Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via Plug-and-Display technology

Cheng, K., Zhao, R., Li, Y., Qi, Y., Wang, Y., Zhang, Y., Qin, H., Qin, Y., Chen, L., Li, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22308-8 · Cited by 480 · see citing works

Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity

Griffin, G. K., Wu, J., Iracheta-Vellve, A., Patti, J. C., Hsu, J., Davis, T., Dele-Oni, D., Du, P. P., Halawi, A. G., Ishizuka, J. J., et al. (2021) · Nature · doi:10.1038/s41586-021-03520-4 · Cited by 370 · see citing works

Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy

Yamazaki, T., Kirchmair, A., Sato, A., Buqué, A., Rybstein, M., Petroni, G., Bloy, N., Finotello, F., Stafford, L., Navarro Manzano, E., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0751-0 · Cited by 359 · see citing works

Understanding the tumor microenvironment for effective immunotherapy

Sadeghi Rad, H., Monkman, J., Warkiani, M. E., Ladwa, R., O'Byrne, K., Rezaei, N., & Kulasinghe, A. (2021) · Medicinal Research Reviews · doi:10.1002/med.21765 · Cited by 334 · see citing works

Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy

Riera-Domingo, C., Audigé, A., Granja, S., Cheng, W.-C., Ho, P.-C., Baltazar, F., Stockmann, C., & Mazzone, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00018.2019 · Cited by 310 · see citing works

WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment

Li, X., Xiang, Y., Li, F., Yin, C., Li, B., & Ke, X. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02293 · Cited by 291 · see citing works

Trial watch: STING agonists in cancer therapy

Le Naour, J., Zitvogel, L., Galluzzi, L., Vacchelli, E., & Kroemer, G. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1777624 · Cited by 289 · see citing works

Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors

Xiao, Z., Todd, L., Huang, L., Noguera-Ortega, E., Lu, Z., Huang, L., Kopp, M., Li, Y., Pattada, N., Zhong, W., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40850-5 · Cited by 272 · see citing works

Trial watch: TLR3 agonists in cancer therapy

Le Naour, J., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1771143 · Cited by 239 · see citing works

Immune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms

Moslehi, J., Lichtman, A. H., Sharpe, A. H., Galluzzi, L., & Kitsis, R. N. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145186 · Cited by 237 · see citing works

Immunomodulation by targeted anticancer agents

Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212 · see citing works

Pharmacological modulation of nucleic acid sensors - therapeutic potential and persisting obstacles

Vanpouille-Box, C., Hoffmann, J. A., & Galluzzi, L. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0043-2 · Cited by 183 · see citing works

Immunomodulation by anticancer cell cycle inhibitors

Petroni, G., Formenti, S. C., Chen-Kiang, S., & Galluzzi, L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0300-y · Cited by 163 · see citing works

Autophagy in hepatic adaptation to stress

Hazari, Y., Bravo-San Pedro, J. M., Hetz, C., Galluzzi, L., & Kroemer, G. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.026 · Cited by 151 · see citing works

Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients

Rodriguez-Ruiz, M. E., Buqué, A., Hensler, M., Chen, J., Bloy, N., Petroni, G., Sato, A., Yamazaki, T., Fucikova, J., & Galluzzi, L. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1655964 · Cited by 147 · see citing works

Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer

Buqué, A., Bloy, N., Perez-Lanzón, M., Iribarren, K., Humeau, J., Pol, J. G., Levesque, S., Mondragon, L., Yamazaki, T., Sato, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17644-0 · Cited by 138 · see citing works

TBKBP1 and TBK1 form a growth factor signalling axis mediating immunosuppression and tumourigenesis

Zhu, L., Li, Y., Xie, X., Zhou, X., Gu, M., Jie, Z., Ko, C.-J., Gao, T., Hernandez, B. E., Cheng, X., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0429-8 · Cited by 109 · see citing works

Trial Watch: experimental TLR7/TLR8 agonists for oncological indications

Frega, G., Wu, Q., Le Naour, J., Vacchelli, E., Galluzzi, L., Kroemer, G., & Kepp, O. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1796002 · Cited by 108 · see citing works

Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer

Nam, G.-H., Kwon, M., Jung, H., Ko, E., Kim, S. A., Choi, Y., Song, S. J., Kim, S., Lee, Y., Kim, G. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002474 · Cited by 82 · see citing works

TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells

Mao, L., Xiao, Y., Yang, Q.-C., Yang, S.-C., Yang, L.-L., & Sun, Z.-J. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105472 · Cited by 68 · see citing works

Cell Fate Reprogramming in the Era of Cancer Immunotherapy

Zimmermannova, O., Caiado, I., Ferreira, A. G., & Pereira, C.-F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.714822 · Cited by 56 · see citing works

Bridging the gap between tumor-on-chip and clinics: a systematic review of 15 years of studies

Bouquerel, C., Dubrova, A., Hofer, I., Phan, D. T. T., Bernheim, M., Ladaigue, S., Cavaniol, C., Maddalo, D., Cabel, L., Mechta-Grigoriou, F., et al. (2023) · Lab on a Chip · doi:10.1039/d3lc00531c · Cited by 58 · see citing works

Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients

Truxova, I., Kasikova, L., Salek, C., Hensler, M., Lysak, D., Holicek, P., Bilkova, P., Holubova, M., Chen, X., Mikyskova, R., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.223933 · Cited by 56 · see citing works

Immunotherapy for Cancer: Harnessing the Power of the Immune SystemPreprint

Bashir, D. (2023) · doi:10.31219/osf.io/mjx9n

Immunotherapy: Reshape the Tumor Immune Microenvironment

Bingzhe, L. V., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844142 · Cited by 489 · see citing works

The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment

Kim, S. K., & Cho, S. W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.868695 · Cited by 473 · see citing works

Tumor-derived extracellular vesicles in melanoma immune response and immunotherapy

Zhou, Q., Yan, Y., Li, Y., Fu, H., Lu, D., Li, Z., Wang, Y., Wang, J., Zhu, H., Ren, J., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113790 · Cited by 23 · see citing works

Differential Role of PD-1 Expressed by Various Immune and Tumor Cells in the Tumor Immune Microenvironment: Expression, Function, Therapeutic Efficacy, and Resistance to Cancer Immunotherapy

Kim, M. J., & Ha, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.767466 · Cited by 42 · see citing works